Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Briggs

Showing results (141-150 of 229) with videos related to

Pageof 23
Sort By:
British Journal of Cancer|April 9, 2020
Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinomaAndrew Briggs, Bruno Daniele, Katherine Dick, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 24, 2005
Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force reportScott Ramsey, Richard Willke, Andrew Briggs, et al.
Pharmacoeconomics|June 18, 2005
Incorporation of uncertainty in health economic modelling studiesAnthony O'Hagan, Christopher McCabe, Ron Akehurst, et al.
Health Economics|July 5, 2016
Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology AppraisalAlec Morton, Amanda I Adler, David Bell, et al.
Diabetologia|August 11, 2020
Type 2 diabetes remission: 2 year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/Counterweight-Plus weight management programmeYiqiao Xin, Andrew Davies, Andrew Briggs, et al.
Orphanet Journal of Rare Diseases|March 19, 2025
Development of the natural history component of an early economic model for primary sclerosing cholangitisChristopher Bowlus, Cynthia Levy, Kris V Kowdley, et al.
European Heart Journal|February 25, 2006
Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of riskJaap W Deckers, Dick M Goedhart, Eric Boersma, et al.
Heart (British Cardiac Society)|December 1, 2006
Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA studyAndrew Briggs, Borislava Mihaylova, Mark Sculpher, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2013
Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task forceLouis P Garrison, Adrian Towse, Andrew Briggs, et al.
BMJ Evidence-Based Medicine|March 20, 2025
Is health technology assessment value for money? Estimating the return on investment of health technology assessment in India (HTAIn)Pankaj Bahuguna, Peter Alan Baker, Andrew Briggs, et al.
Pageof 23

Showing results (141-150 of 229) with videos related to

Sort By:
Pageof 23
British Journal of Cancer|April 9, 2020
Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinomaAndrew Briggs, Bruno Daniele, Katherine Dick, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 24, 2005
Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force reportScott Ramsey, Richard Willke, Andrew Briggs, et al.
Pharmacoeconomics|June 18, 2005
Incorporation of uncertainty in health economic modelling studiesAnthony O'Hagan, Christopher McCabe, Ron Akehurst, et al.
Health Economics|July 5, 2016
Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology AppraisalAlec Morton, Amanda I Adler, David Bell, et al.
Diabetologia|August 11, 2020
Type 2 diabetes remission: 2 year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/Counterweight-Plus weight management programmeYiqiao Xin, Andrew Davies, Andrew Briggs, et al.
Orphanet Journal of Rare Diseases|March 19, 2025
Development of the natural history component of an early economic model for primary sclerosing cholangitisChristopher Bowlus, Cynthia Levy, Kris V Kowdley, et al.
European Heart Journal|February 25, 2006
Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of riskJaap W Deckers, Dick M Goedhart, Eric Boersma, et al.
Heart (British Cardiac Society)|December 1, 2006
Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA studyAndrew Briggs, Borislava Mihaylova, Mark Sculpher, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2013
Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task forceLouis P Garrison, Adrian Towse, Andrew Briggs, et al.
BMJ Evidence-Based Medicine|March 20, 2025
Is health technology assessment value for money? Estimating the return on investment of health technology assessment in India (HTAIn)Pankaj Bahuguna, Peter Alan Baker, Andrew Briggs, et al.
Pageof 23